Oncosoft (CEO Jinsung Kim) announced today that it has finalized a Series B investment of 11 billion won.
The Series B round was led by existing investors BNH Investment, HB Investment, and DevSisters Ventures, with new investors Bon Angels Venture Partners and LB Investment joining as follow-on investors.
Oncosoft is a company that develops AI-based software (SW) specialized for radiation therapy. Radiation therapy is one of the main cancer treatments that kills cancer cells and inhibits their growth by irradiating focal areas of the body with radiation energy or injecting radioactive substances. Currently, 49% of new cancer patients receive radiation therapy, creating a high demand for accurate and safe treatment solutions.
OncoStudio, the company's first product, is a solution that uses AI technology to precisely segment normal organs and tumor sites, which minimizes the amount of radiation to normal organs during radiation therapy, reducing side effects and improving the safety of treatment. OncoStudio has been used in major medical institutions such as Samsung Medical Center and Severance Hospital since obtaining a domestic license in 2022.
In addition, OncoSoft has completed the development of OncoFlow, which enables integrated management of the entire radiation therapy process, and is currently accelerating the development of OncoPlan, a radiation therapy planning system (TPS) that includes radiation anticancer drug treatment planning.
Meanwhile, OncoSoft, founded in 2019 by Dr. Jinsung Kim, a professor of radiation oncology at Yonsei University School of Medicine, has recently hired Chief Financial Officer (CFO) Yeonkyung Lee and is preparing to go public. The funds will be used to develop next-generation healthcare AI solutions and expand into the global market.
